新闻源 财富源

2019年10月14日 星期一

康缘药业(600557)公告正文

康缘药业:2011年半年度报告摘要

公告日期:2011-08-13

    江苏康缘药业股份有限公司 (股票代码:600557)              2011 年半年度报告摘要
    江苏康缘药业股份有限公司
    2011 年半年度报告摘要
    §1 重要提示
    1.1 本公司董事会、监事会及董事、监事、高级管理人员保证本报告所载资料不存在任何虚
    假记载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带
    责任。
    本半年度报告摘要摘自半年度报告全文,投资者欲了解详细内容,应当仔细阅读半年度
    报告全文。
    1.2 公司全体董事出席董事会会议。
    1.3 公司半年度财务报告未经审计。
    1.4 是否存在被控股股东及其关联方非经营性占用资金情况?否
    1.5 是否存在违反规定决策程序对外提供担保的情况?否
    1.6 公司负责人肖伟、主管会计工作负责人陈友龙及会计机构负责人(会计主管人员)焦晓
    杉声明:保证半年度报告中财务报告的真实、完整。
    §2 公司基本情况
    2.1 基本情况简介
    股票简称        康缘药业
    股票代码        600557
    股票上市交易所      上海证券交易所
    董事会秘书                         证券事务代表
    姓名                         程 凡                             解金亮
    联系地址        江苏省连云港市新浦区海昌南路 58 号   江苏省连云港市新浦区海昌南路 58 号
    电话                    0518-85521990                      0518-85521990
    传真                    0518-85521990                      0518-85521990
    电子信箱                   chf@kanion.com                     fzb@kanion.com
    2.2 主要财务数据和指标
    2.2.1 主要会计数据和财务指标
    第 1 页 共 20 页
    江苏康缘药业股份有限公司 (股票代码:600557)                    2011 年半年度报告摘要
    单位:元 币种:人民币
    上年度期末         本报告期末比上
    本报告期末
    调整后   调整前      年度期末增减(%)
    总资产                            2,276,504,864.91        1,987,481,196.13                   14.54
    所有者权益(或股东权益)          1,344,290,326.95        1,209,173,803.04                   11.17
    归属于上市公司股东的每股净
    3.176       2.857     2.909                   11.17
    资产(元/股)
    上年同期              本报告期比上
    报告期(1-6 月)
    调整后   调整前          年同期增减(%)
    营业利润                             111,334,071.20         96,263,407.78                    15.66
    利润总额                             117,002,218.28         105,773,411.08                   10.62
    归属于上市公司股东的净利润           96,715,431.24           91,361,141.07                    5.86
    归属于上市公司股东的扣除非
    92,398,929.71          83,285,728.64                    10.94
    经常性损益的净利润
    基本每股收益(元)                                   0.23     0.22        0.29                  4.55
    扣除非经常性损益后的基本每
    0.22     0.20        0.26                 10.00
    股收益(元)
    稀释每股收益(元)                                   0.23     0.22        0.29                  4.55
    加权平均净资产收益率(%)                            7.71                 8.28   减少 0.57 个百分点
    经营活动产生的现金流量净额           10,052,527.15          28,463,894.99                   -64.68
    每股经营活动产生的现金流量
    0.0238      0.0673    0.0890                  -64.64
    净额(元)
    2010 年 8 月 20 日,公司实施半年度资本公积金转增股本方案,以每 10 股转增 3 股的
    比例转增股本,转增后公司总股本由 319,728,224 股增加为 415,646,691 股;2011 年 6 月
    17 日,公司实施 A 股限制性股票激励计划,首次授予 62 名激励对象共 7,600,000 股,总股
    本由 415,646,691 股增加为 423,246,691 股。以上原因致使相关指标被相应摊薄。
    2.2.2 非经常性损益项目
    √适用 □不适用
    单位:元 币种:人民币
    非经常性损益项目                                         金 额
    非流动资产处置损益                                                                      -9,661.18
    计入当期损益的政府补助(与企业业务密切相关,按
    5,484,591.72
    照国家统一标准定额或定量享受的政府补助除外)
    除上述各项之外的其他营业外收入和支出                                                   193,216.54
    所得税影响额                                                                          -951,905.36
    少数股东权益影响额(税后)                                                            -399,740.19
    合 计                                                          4,316,501.53
    第 2 页 共 20 页
    江苏康缘药业股份有限公司 (股票代码:600557)                      2011 年半年度报告摘要
    §3 股本变动及股东情况
    3.1 股份变动情况表
    √适用 □不适用
    单位:股
    本次变动前           本次变动增减(+,-)            本次变动后
    数量        比例(%)      其他          小计             数量           比例(%)
    一、有限售条件股份             108,539,579       26.11   7,600,000    7,600,000    116,139,579             27.44
    1、国家持股
    2、国有法人持股
    3、其他内资持股                108,539,579       26.11   7,600,000    7,600,000    116,139,579             27.44
    其中:境内非国有法人持股       108,539,579       26.11                             108,539,579             25.64
    境内自然人持股                                     7,600,000    7,600,000       7,600,000              1.80
    4、外资持股
    其中:境外法人持股
    境外自然人持股
    二、无限售条件流通股份         307,107,112       73.89                             307,107,112             72.56
    1、人民币普通股                307,107,112       73.89                             307,107,112             72.56
    2、境内上市的外资股
    3、境外上市的外资股
    4、其他
    三、股份总数                   415,646,691     100.00    7,600,000    7,600,000    423,246,691            100.00
    3.2 股东数量和持股情况
    单位:股
    报告期末股东总数                                                                                         29,679 户
    前十名股东持股情况
    持有有限售
    持股                      报告期                         质押或冻结
    股东名称              股东性质                持股总数                    条件股份数
    比例                      内增减                         的股份数量
    量
    境内非
    江苏康缘集团有限责任公司                  25.64%     108,539,579                  108,539,579              无
    国有法人
    连云港康贝尔医疗器械有限      境内非
    5.23%     22,132,338                               0            无
    公司                          国有法人
    中国农业银行-长城安心回
    其他       3.07%     13,000,000                               0           未知
    报混合型证券投资基金
    境内
    肖 伟                                      2.79%     11,808,082                               0            无
    自然人
    中国平安人寿保险股份有限
    其他       2.43%     10,301,778    3,323,777                  0           未知
    公司-传统-普通保险产品
    中国工商银行-国投瑞银核
    其他       2.05%      8,695,122    8,695,122                  0           未知
    心企业股票型证券投资基金
    第 3 页 共 20 页
    江苏康缘药业股份有限公司 (股票代码:600557)                     2011 年半年度报告摘要
    中国工商银行股份有限公司
    -广发行业领先股票型证券       其他         1.95%     8,265,515      1,974,817                0        未知
    投资基金
    中国银行-招商先锋证券投
    其他         1.53%     6,459,769      2,299,935                0        未知
    资基金
    中国工商银行-招商核心价
    其他         1.37%     5,813,148        882,090                0        未知
    值混合型证券投资基金
    中国建设银行-长城消费增
    其他         1.33%     5,610,523        203,400                0        未知
    值股票型证券投资基金
    前十名无限售条件股东持股情况
    股东名称                                 持有无限售条件股份的数量          股份种类
    连云港康贝尔医疗器械有限公司                                                     22,132,338   人民币普通股
    中国农业银行-长城安心回报混合型证券投资基金                                     13,000,000   人民币普通股
    肖 伟                                                                            11,808,082   人民币普通股
    中国平安人寿保险股份有限公司-传统-普通保险产品                                 10,301,778   人民币普通股
    中国工商银行-国投瑞银核心企业股票型证券投资基金                                  8,695,122   人民币普通股
    中国工商银行股份有限公司-广发行业领先股票型证券投
    8,265,515   人民币普通股
    资基金
    中国银行-招商先锋证券投资基金                                                    6,459,769   人民币普通股
    中国工商银行-招商核心价值混合型证券投资基金                                      5,813,148   人民币普通股
    中国建设银行-长城消费增值股票型证券投资基金                                      5,610,523   人民币普通股
    中国工商银行股份有限公司-汇添富医药保健股票型证券
    5,595,561   人民币普通股
    投资基金
    前十大股东中,江苏康缘集团有限责任公司和肖伟先生存在关联关系,肖伟先生
    上述股东关联关系或     为江苏康缘集团有限责任公司第一大股东。公司未知其他股东之间、其他股东与前十
    一致行动的说明         名无限售条件股东之间是否存在关联关系或一致行动人关系;公司未知前十名无限售
    条件股东之间是否存在关联关系或一致行动人关系。
    3.3 控股股东及实际控制人变更情况
    □适用 √不适用
    §4 董事、监事和高级管理人员情况
    4.1 董事、监事和高级管理人员持股变动
    √适用 □不适用
    单位:股
    年初持      本期增持   本期减持       期末持                        被授予的限制
    姓 名       职 务                                                       变动原因
    股数        股份数量   股份数量         股数                          性股票数量
    系公司实行 A
    常务副
    郭传宝                     0       500,000         0       500,000   股限制性股票              500,000
    总经理
    激励计划所致。
    王振中    副总经理         0       400,000         0       400,000   系公司实行 A              400,000
    第 4 页 共 20 页
    江苏康缘药业股份有限公司 (股票代码:600557)                           2011 年半年度报告摘要
    股限制性股票
    激励计划所致。
    系公司实行 A
    杨永春      副总经理       0        350,000          0       350,000      股限制性股票                350,000
    激励计划所致。
    系公司实行 A
    刘五生      副总经理       0        350,000          0       350,000      股限制性股票                350,000
    激励计划所致。
    系公司实行 A
    陈友龙      财务总监       0        200,000          0       200,000      股限制性股票                200,000
    激励计划所致。
    §5 董事会报告
    5.1 主营业务分行业、产品情况表
    单位:元 币种:人民币
    分行业或                                         营业利   营业收入比上       营业成本比上         营业利润率比
    营业收入         营业成本
    分产品                                         润率(%)   年同期增减(%)     年同期增减(%)     上年同期增减(%)
    分行业
    医药工业      692,517,806.65   185,641,060.77      73.19           17.37              33.38    减少 3.22 个百分点
    医药贸易       43,304,572.54   38,307,131.85       11.54           30.54              34.32    减少 2.49 个百分点
    分产品(母公司)
    胶囊          342,024,425.37   94,119,098.28       72.48           -7.00              28.51    减少 7.60 个百分点
    注射液        181,887,799.53   48,554,128.51       73.31           29.10               9.99    增加 4.64 个百分点
    片丸剂         17,940,982.98   16,866,576.20        5.99           58.67              26.61   增加 23.81 个百分点
    口服液         12,496,983.18    3,181,923.69       74.54          -27.61             -63.24   增加 24.69 个百分点
    颗粒剂、
    4,053,676.19    3,074,161.31       24.16           21.57              40.40   减少 10.17 个百分点
    冲剂
    5.2 主营业务分地区情况
    单位:元 币种:人民币
    地区(母公司)                   营业收入                     营业收入比上年增减(%)
    华东地区                         238,288,504.09                                     -5.88
    华中地区                             70,012,457.09                                      0.58
    华南地区                             68,296,155.18                                      0.48
    华北地区                             65,323,431.18                                      3.20
    西南地区                             60,753,020.68                                  33.81
    东北地区                             39,984,097.17                                  30.25
    西北地区                             15,746,201.86                                  51.30
    5.3 主营业务及其结构发生重大变化的原因说明
    第 5 页 共 20 页
    江苏康缘药业股份有限公司 (股票代码:600557)                    2011 年半年度报告摘要
    □ 适用 √不适用
    5.4主营业务盈利能力(毛利率)与上年相比发生重大变化的原因说明
    □适用 √不适用
    5.5 利润构成与上年度相比发生重大变化的原因分析
    □适用 √不适用
    5.6 募集资金使用情况
    5.6.1 募集资金运用
    √适用 □不适用
    单位:万元 币种:人民币
    本报告期已使用募集资金总额                   384.10
    募集资金总额                        28245.70
    已累计使用募集资金总额                 22438.58
    是否变         拟投入     实际投       是否符合     产生收益
    承诺项目
    更项目           金额     入金额       计划进度       情况
    现代中药注射剂生产线技术改造项目              否         15188.00    16056.65        是          2975.70
    散结镇痛胶囊产业化项目                        否          6268.00     3092.79        否
    创新中药研究与(GLP)安全评价中心项目         否          8260.00     3289.14        否
    合计                        /          29716.00    22438.58        /            /
    (1)现代中药注射剂生产线技术改造项目已于 2010 年末竣工投产,2011 年 1-6 月收入
    17696.00 万元,产生收益 2975.70 万元。
    未达到计        (2)散结镇痛胶囊产业化项目,拟投入金额为 6268.00 万元,累计投入金额为 3092.79
    划 进 度 和 万元,目前“利用一期提取车间改造成中药精制车间工程”、“新建质检中心工程”已完工;“利
    预 计 收 益 用一期综合制剂车间改造成胶囊生产车间工程”尚未开工,主要系为适应新版 GMP 标准对药品
    的说明(分 生产软、硬件条件要求的提高,正在对原有车间设计方案进行调整,预计 2012 年完工。
    具体项目)      (3)创新中药研究与(GLP)安全评价中心项目,拟投入金额为 8260.00 万元,累计投入
    金额为 3289.14 万元,已支付土地款,但由于当地政府对该项目地块周边范围规划调整,目前
    尚未获得土地权证和相关施工许可证,目前公司正在积极努力协调。
    5.7 变更项目情况
    □适用 √不适用
    5.8 非募集资金项目情况
    单位:万元 币种:人民币
    项目名称                      项目金额                      项目进度
    行政办公楼                                         362.21                           15.41%
    培训中心                                           283.60                           14.18%
    中试研发平台                                     2,405.67                           55.30%
    质检综合楼                                       1,474.89                           52.60%
    北京研发总部装修                                   807.54                           74.09%
    上市品种再评价研发中心                             105.20                            2.15%
    康缘弘道软胶囊生产线                             5,730.23                           11.94%
    合 计                               11,169.34                                /
    第 6 页 共 20 页
    江苏康缘药业股份有限公司 (股票代码:600557)           2011 年半年度报告摘要
    5.9 董事会下半年的经营计划修改计划
    □适用 √不适用
    5.10 预测年初至下一报告期期末的累计净利润可能为亏损或者与上年同期相比发生大幅
    度变动的警示及说明
    □适用 √不适用
    5.11 公司董事会对会计师事务所本报告期“非标准审计报告”的说明
    □适用 √不适用
    5.12 公司董事会对会计师事务所上年度“非标准审计报告”涉及事项的变化及处理情况的
    说明
    □适用 √不适用
    §6 重要事项
    6.1 收购资产
    □适用 √不适用
    6.2 出售资产
    □适用 √不适用
    6.3 担保事项
    □适用 √不适用
    6.4 关联债权债务往来
    □适用 √不适用
    6.5 重大诉讼仲裁事项
    □适用 √不适用
    6.6 其他重大事项及其影响和解决方案的分析说明
    6.6.1 证券投资情况
    □适用   √不适用
    6.6.2 持有其他上市公司股权情况
    □适用   √不适用
    6.6.3 持有非上市金融企业股权情况
    □适用   √不适用
    §7财务会计报告
    第 7 页 共 20 页
    江苏康缘药业股份有限公司 (股票代码:600557)                         2011 年半年度报告摘要
    7.1 审计意见
    财务报告                    √未经审计                          □审计
    7.2 财务报表
    合并资产负债表(一)
    2011 年 6 月 30 日
    编制单位:江苏康缘药业股份有限公司
    单位:元 币种:人民币
    项    目                      附 注           期末余额                年初余额
    流动资产
    货币资金                                   5-1           189,115,620.21          151,523,396.75
    结算备付金
    交易性金融资产                             5-2             1,000,000.00
    应收票据                                   5-3           299,008,895.11          259,445,585.48
    应收账款                                   5-4           594,108,138.42          457,703,102.01
    预付款项                                   5-5           147,313,459.85          129,558,034.13
    其他应收款                                 5-6            56,577,961.11           47,924,411.81
    买入返售金融资产
    存货                                       5-7            77,394,403.11           80,636,180.50
    一年内到期的非流动资产
    其他流动资产
    流动资产合计                                         1,364,518,477.81       1,126,790,710.68
    非流动资产
    长期应收款
    长期股权投资                               5-8             4,005,156.33
    投资性房地产
    固定资产                                   5-9           569,463,371.35          584,083,300.14
    在建工程                                  5-10           148,492,562.35           99,901,320.99
    工程物资
    固定资产清理
    油气资产
    无形资产                                  5-11           107,775,307.38           94,352,106.33
    开发支出                                  5-12            20,600,000.00           20,600,000.00
    商誉                                      5-13            58,988,858.14           58,988,858.14
    长期待摊费用                              5-14                91,954.28               571,754.28
    递延所得税资产                            5-15             2,569,177.27            2,193,145.57
    其他非流动资产
    非流动资产合计                                        911,986,387.10           860,690,485.45
    资产总计                                        2,276,504,864.91       1,987,481,196.13
    法定代表人:肖 伟               主管会计工作负责人:陈友龙          会计机构负责人:焦晓杉
    第 8 页 共 20 页
    江苏康缘药业股份有限公司 (股票代码:600557)                  2011 年半年度报告摘要
    合并资产负债表(二)
    2011 年 6 月 30 日
    编制单位:江苏康缘药业股份有限公司
    单位:元 币种:人民币
    项   目                    附 注           期末余额              年初余额
    流动负债
    短期借款                              5-17           356,313,668.10        310,089,895.30
    应付票据                              5-18            38,600,000.00         25,000,000.00
    应付账款                              5-19           144,437,542.70        132,276,598.40
    预收款项                              5-20            39,705,891.35         36,201,287.72
    应付手续费及佣金
    应付职工薪酬                          5-21             4,851,898.13          5,644,058.53
    应交税费                              5-22            42,998,911.55         28,849,214.47
    应付利息                              5-23             1,472,135.04            707,545.90
    应付股利                              5-24            10,001,488.08
    其他应付款                            5-25           111,718,640.21        117,037,070.55
    一年内到期的非流动负债
    其他流动负债                          5-26            25,026,499.53         25,856,416.25
    流动负债合计                                      775,126,674.69        681,662,087.12
    非流动负债
    长期借款                              5-27           118,000,000.00         58,000,000.00
    长期应付款
    专项应付款                            5-28             3,525,285.00          3,525,285.00
    递延所得税负债
    其他非流动负债
    非流动负债合计                                    121,525,285.00         61,525,285.00
    负债合计                                         896,651,959.69       743,187,372.12
    所有者权益(或股东权益)
    实收资本(或股本)                    5-29           423,246,691.00        415,646,691.00
    资本公积                              5-30           294,026,072.13        238,318,072.13
    减:库存股
    专项储备
    盈余公积                              5-31           100,134,392.44        100,134,392.44
    一般风险准备
    未分配利润                            5-32           527,430,917.35        455,654,287.57
    外币报表折算差额                                        -547,745.97           -579,640.10
    归属于母公司所有者权益合计                         1,344,290,326.95      1,209,173,803.04
    少数股东权益                                          35,562,578.27         35,120,020.97
    所有者权益合计                                 1,379,852,905.22     1,244,293,824.01
    负债和所有者权益总计                             2,276,504,864.91     1,987,481,196.13
    法定代表人:肖 伟          主管会计工作负责人:陈友龙           会计机构负责人:焦晓杉
    第 9 页 共 20 页
    江苏康缘药业股份有限公司 (股票代码:600557)                  2011 年半年度报告摘要
    母公司资产负债表(一)
    2011 年 6 月 30 日
    编制单位:江苏康缘药业股份有限公司
    单位:元 币种:人民币
    项    目                  附 注           期末余额              年初余额
    流动资产
    货币资金                                             158,530,734.36        106,838,320.05
    交易性金融资产                                         1,000,000.00
    应收票据                                             247,230,162.45        224,091,682.55
    应收账款                              11-1           486,549,991.78        358,664,162.46
    预付款项                                             131,835,701.26        118,034,244.42
    应收利息
    应收股利                                               3,792,600.00
    其他应收款                            11-2            25,159,458.23         21,612,672.05
    存货                                                  60,217,510.52         69,622,885.58
    一年内到期的非流动资产
    其他流动资产
    流动资产合计                                     1,114,316,158.60       898,863,967.11
    非流动资产
    可供出售金融资产
    持有至到期投资
    长期应收款
    长期股权投资                          11-3           171,741,352.00        167,736,195.67
    投资性房地产
    固定资产                                             533,501,743.75        548,271,370.83
    在建工程                                              91,190,278.26         63,163,381.26
    工程物资
    固定资产清理
    生产性生物资产
    油气资产
    无形资产                                              77,577,436.18         69,099,404.73
    开发支出                                              20,600,000.00         20,600,000.00
    商誉
    长期待摊费用
    递延所得税资产                                         1,131,133.54            949,446.47
    其他非流动资产
    非流动资产合计                                    895,741,943.73        869,819,798.96
    资产总计                                    2,010,058,102.33     1,768,683,766.07
    法定代表人:肖 伟           主管会计工作负责人:陈友龙          会计机构负责人:焦晓杉
    第 10 页 共 20 页
    江苏康缘药业股份有限公司 (股票代码:600557)                  2011 年半年度报告摘要
    母公司资产负债表(二)
    2011 年 6 月 30 日
    编制单位:江苏康缘药业股份有限公司
    单位:元 币种:人民币
    项   目                    附 注           期末余额              年初余额
    流动负债
    短期借款                                             300,000,000.00        247,000,000.00
    交易性金融负债
    应付票据                                              20,000,000.00         23,000,000.00
    应付账款                                             111,624,828.68        108,376,401.87
    预收款项                                              36,607,851.31         31,654,445.34
    应付职工薪酬                                           3,488,046.16          4,268,165.98
    应交税费                                              35,893,863.58         21,455,830.02
    应付利息                                               1,472,135.04            554,940.63
    应付股利                                               7,794,088.08
    其他应付款                                            83,130,339.85         93,799,585.33
    一年内到期的非流动负债
    其他流动负债                                          24,926,499.53         25,856,416.25
    流动负债合计                                      624,937,652.23        555,965,785.42
    非流动负债
    长期借款                                              48,000,000.00          8,000,000.00
    应付债券
    长期应付款
    专项应付款                                             3,525,285.00          3,525,285.00
    预计负债
    递延所得税负债
    其他非流动负债
    非流动负债合计                                     51,525,285.00         11,525,285.00
    负债合计                                        676,462,937.23        567,491,070.42
    所有者权益(或股东权益)
    实收资本(或股本)                                   423,246,691.00        415,646,691.00
    资本公积                                             294,026,072.13        238,318,072.13
    减:库存股
    专项储备
    盈余公积                                              98,327,231.88         98,327,231.88
    一般风险准备
    未分配利润                                           517,995,170.09        448,900,700.64
    所有者权益(或股东权益)合计                            1,333,595,165.10     1,201,192,695.65
    负债和所有者权益总计                                    2,010,058,102.33     1,768,683,766.07
    法定代表人:肖 伟          主管会计工作负责人:陈友龙           会计机构负责人:焦晓杉
    第 11 页 共 20 页
    江苏康缘药业股份有限公司 (股票代码:600557)               2011 年半年度报告摘要
    合并利润表
    2011 年 1—6 月
    编制单位:江苏康缘药业股份有限公司
    单位:元 币种:人民币
    项   目                        附 注    本期金额              上期金额
    一、营业总收入                                             736,548,835.27       625,108,609.21
    其中:营业收入                                5-33    736,548,835.27       625,108,609.21
    利息收入
    已赚保费
    手续费及佣金收入
    二、营业总成本                                             625,219,920.40       530,333,358.39
    其中:营业成本                                5-33    224,161,965.51       169,531,294.75
    利息支出
    手续费及佣金支出
    营业税金及附加                          5-34     10,879,248.77         9,181,593.50
    销售费用                                5-35    281,529,611.28       249,785,420.08
    管理费用                                5-36     88,646,663.14        92,829,619.34
    财务费用                                5-37     18,075,272.71         6,430,104.02
    资产减值损失                            5-38      1,927,158.99         2,575,326.70
    投资收益(损失以“-”号填列)                5-39          5,156.33         1,488,156.96
    其中:对联营企业和合营企业的投资收益
    汇兑收益(损失以“-”号填列)
    三、营业利润(亏损以“-”号填列)                         111,334,071.20        96,263,407.78
    加:营业外收入                                5-40      5,731,702.40         9,604,104.47
    减:营业外支出                                5-41         63,555.32              94,101.17
    其中:非流动资产处置损失
    四、利润总额(亏损总额以“-”号填列)                     117,002,218.28       105,773,411.08
    减:所得税费用                                5-42     17,637,708.51        14,243,097.17
    五、净利润(净亏损以“-”号填列)                          99,364,509.77        91,530,313.91
    归属于母公司所有者的净利润                             96,715,431.24        91,361,141.07
    少数股东损益                                            2,649,078.53              169,172.84
    六、每股收益
    (一)基本每股收益                             12-2                0.23                  0.22
    (二)稀释每股收益                             12-2                0.23                  0.22
    七、其他综合收益
    八、综合收益总额                                            99,364,509.77        91,530,313.91
    归属于母公司所有者的综合收益总额                       96,715,431.24        91,361,141.07
    归属于少数股东的综合收益总额
    法定代表人:肖 伟             主管会计工作负责人:陈友龙     会计机构负责人:焦晓杉
    第 12 页 共 20 页
    江苏康缘药业股份有限公司 (股票代码:600557)               2011 年半年度报告摘要
    母公司利润表
    2011 年 1—6 月
    编制单位:江苏康缘药业股份有限公司
    单位:元 币种:人民币
    项   目                        附 注    本期金额             上期金额
    一、营业收入                                       11-4    559,199,903.26      542,322,575.84
    减:营业成本                                  11-4    166,009,660.88      143,273,130.10
    营业税金及附加                                      8,504,568.27        8,203,507.88
    销售费用                                          201,686,662.25      203,264,981.05
    管理费用                                           63,700,736.27       85,879,816.18
    财务费用                                           15,076,854.15        6,244,475.16
    资产减值损失                                        1,258,416.91        1,492,036.51
    投资收益(损失以“-”号填列)            11-5      3,797,756.33        1,485,395.32
    二、营业利润(亏损以“-”号填列)                         106,760,760.86       95,450,024.28
    加:营业外收入                                          3,548,494.70        9,539,111.60
    减:营业外支出                                             55,388.25              77,683.76
    其中:非流动资产处置损失
    三、利润总额(亏损总额以“-”号填列)                     110,253,867.31      104,911,452.12
    减:所得税费用                                         16,220,596.40       13,787,991.80
    四、净利润(净亏损以“-”号填列)                          94,033,270.91       91,123,460.32
    五、每股收益
    (一)基本每股收益                                                 0.22                 0.22
    (二)稀释每股收益                                                 0.22                 0.22
    六、其他综合收益
    七、综合收益总额                                            94,033,270.91       91,123,460.32
    法定代表人:肖 伟             主管会计工作负责人:陈友龙      会计机构负责人:焦晓杉
    第 13 页 共 20 页
    江苏康缘药业股份有限公司 (股票代码:600557)                2011 年半年度报告摘要
    合并现金流量表
    2011 年 1—6 月
    编制单位:江苏康缘药业股份有限公司                                单位:元 币种:人民币
    项   目                        附 注     本期金额             上期金额
    一、经营活动产生的现金流量
    销售商品、提供劳务收到的现金                                691,735,123.21      539,173,615.45
    收到的税费返还                                                4,089,538.05        2,923,787.73
    收到其他与经营活动有关的现金                       5-44      32,025,048.10       20,359,482.64
    经营活动现金流入小计                                       727,849,709.36       562,456,885.82
    购买商品、接受劳务支付的现金                                167,028,861.70      110,139,546.44
    支付给职工以及为职工支付的现金                              124,036,777.45       91,589,803.82
    支付的各项税费                                              118,974,143.08       99,769,867.98
    支付其他与经营活动有关的现金                       5-44     307,757,399.98      232,493,772.59
    经营活动现金流出小计                                       717,797,182.21       533,992,990.83
    经营活动产生的现金流量净额                                   10,052,527.15       28,463,894.99
    二、投资活动产生的现金流量
    取得投资收益收到的现金                                                                    2,761.64
    处置固定资产、无形资产和其他长期资产收
    113,175               85,486.48
    回的现金净额
    收到其他与投资活动有关的现金                                     25,770.48
    投资活动现金流入小计                                           138,945.48               88,248.12
    购建固定资产、无形资产和其他长期资产支
    108,295,552.81      178,338,724.47
    付的现金
    投资支付的现金                                                5,000,000.00        4,000,000.00
    支付其他与投资活动有关的现金
    投资活动现金流出小计                                       113,295,552.81       182,338,724.47
    投资活动产生的现金流量净额                                 -113,156,607.33     -182,250,476.35
    三、筹资活动产生的现金流量
    吸收投资收到的现金                                           63,308,000.00
    取得借款收到的现金                                          295,722,872.50      253,996,358.00
    收到其他与筹资活动有关的现金                                 18,019,146.58
    筹资活动现金流入小计                                       377,050,019.08       253,996,358.00
    偿还债务支付的现金                                          209,566,505.42      113,000,000.00
    分配股利、利润或偿付利息支付的现金                           26,836,790.23       38,729,590.64
    支付其他与筹资活动有关的现金
    筹资活动现金流出小计                                       236,403,295.65       151,729,590.64
    筹资活动产生的现金流量净额                                  140,646,723.43      102,266,767.36
    四、汇率变动对现金及现金等价物的影响                            49,580.21               -44,507.03
    五、现金及现金等价物净增加额                                 37,592,223.46      -51,564,321.03
    加:期初现金及现金等价物余额                                151,523,396.75      236,228,252.54
    六、期末现金及现金等价物余额                               189,115,620.21       184,663,931.51
    法定代表人:肖 伟             主管会计工作负责人:陈友龙       会计机构负责人:焦晓杉
    第 14 页 共 20 页
    江苏康缘药业股份有限公司 (股票代码:600557)               2011 年半年度报告摘要
    母公司现金流量表
    2011 年 1—6 月
    编制单位:江苏康缘药业股份有限公司                               单位:元 币种:人民币
    项   目                        附 注    本期金额             上期金额
    一、经营活动产生的现金流量
    销售商品、提供劳务收到的现金                               518,005,492.86      449,514,462.81
    收到的税费返还
    收到其他与经营活动有关的现金                                 7,056,010.58       19,583,392.38
    经营活动现金流入小计                                       525,061,503.44      469,097,855.19
    购买商品、接受劳务支付的现金                               110,195,259.07       59,867,455.41
    支付给职工以及为职工支付的现金                              96,686,708.04       77,981,907.19
    支付的各项税费                                              93,886,687.20       90,886,785.76
    支付其他与经营活动有关的现金                               207,477,888.36      196,882,099.93
    经营活动现金流出小计                                       508,246,542.67      425,618,248.29
    经营活动产生的现金流量净额                                  16,814,960.77       43,479,606.90
    二、投资活动产生的现金流量
    收回投资收到的现金
    处置固定资产、无形资产和其他长期资产收
    113,175.00              81,938.84
    回的现金净额
    处置子公司及其他营业单位收到的现金净额
    收到其他与投资活动有关的现金
    投资活动现金流入小计                                           113,175.00              81,938.84
    购建固定资产、无形资产和其他长期资产支
    73,238,287.00      161,491,439.34
    付的现金
    投资支付的现金                                               5,000,000.00
    支付其他与投资活动有关的现金
    投资活动现金流出小计                                        78,238,287.00      161,491,439.34
    投资活动产生的现金流量净额                                 -78,125,112.00     -161,409,500.50
    三、筹资活动产生的现金流量
    吸收投资收到的现金                                          63,308,000.00
    取得借款收到的现金                                         244,000,000.00      200,000,000.00
    收到其他与筹资活动有关的现金
    筹资活动现金流入小计                                       307,308,000.00      200,000,000.00
    偿还债务支付的现金                                         171,000,000.00      110,000,000.00
    分配股利、利润或偿付利息支付的现金                          23,305,434.46       38,671,047.89
    支付其他与筹资活动有关的现金
    筹资活动现金流出小计                                       194,305,434.46      148,671,047.89
    筹资活动产生的现金流量净额                                 113,002,565.54       51,328,952.11
    四、汇率变动对现金及现金等价物的影响
    五、现金及现金等价物净增加额                                51,692,414.31      -66,600,941.49
    加:期初现金及现金等价物余额                               106,838,320.05      185,052,850.43
    六、期末现金及现金等价物余额                               158,530,734.36      118,451,908.94
    法定代表人:肖 伟             主管会计工作负责人:陈友龙      会计机构负责人:焦晓杉
    第 15 页 共 20 页
    江苏康缘药业股份有限公司 (股票代码:600557)                                                                              2011 年半年度报告摘要
    合并所有者权益变动表
    2011 年 1—6 月
    单位:元 币种:人民币
    本期金额
    归属于母公司所有者权益
    项     目
    实收资本                                                                             少数股东权益      所有者权益合计
    资本公积           盈余公积         未分配利润        其他
    (或股本)
    一、上年年末余额                415,646,691.00     238,318,072.13    100,134,392.44     455,654,287.57   -579,640.10   35,120,020.97    1,244,293,824.01
    二、本年年初余额                415,646,691.00     238,318,072.13    100,134,392.44     455,654,287.57   -579,640.10   35,120,020.97    1,244,293,824.01
    三、本期增减变动金额(减少
    以“-”号填列)                  7,600,000.00     55,708,000.00                         71,776,629.78    31,894.13       442,557.30       135,559,081.21
    (一)净利润                                                                             96,715,431.24                  2,649,078.53        99,364,509.77
    (二)其他综合收益
    上述(一)和(二)小计                                                                   96,715,431.24                  2,649,078.53        99,364,509.77
    (三)所有者投入和减少资本        7,600,000.00      55,708,000.00                                          31,894.13   -2,206,521.23        61,133,372.90
    1.所有者投入资本                 7,600,000.00      55,708,000.00                                                                           63,308,000.00
    3.其他                                                                                                    31,894.13   -2,206,521.23        -2,174,627.10
    (四)利润分配                                                                          -24,938,801.46                                     -24,938,801.46
    1.提取盈余公积
    2.提取一般风险准备
    3.对所有者(或股东)的分配                                                             -24,938,801.46                                     -24,938,801.46
    (五)所有者权益内部结转
    1.资本公积转增资本(或股本)
    四、本期期末余额                423,246,691.00     294,026,072.13    100,134,392.44     527,430,917.35   -547,745.97   35,562,578.27    1,379,852,905.22
    法定代表人:肖 伟                                        主管会计工作负责人:陈友龙                                    会计机构负责人:焦晓杉
    第 16 页 共 20 页
    江苏康缘药业股份有限公司 (股票代码:600557)                                                                              2011 年半年度报告摘要
    上年同期金额
    归属于母公司所有者权益
    项   目
    实收资本                                                                              少数股东权益      所有者权益合计
    资本公积            盈余公积         未分配利润        其他
    (或股本)
    一、上年年末余额                319,728,224.00     334,236,539.13      82,418,125.33    335,804,993.66   -416,654.24    6,409,775.31    1,078,181,003.19
    二、本年年初余额                319,728,224.00     334,236,539.13      82,418,125.33    335,804,993.66   -416,654.24    6,409,775.31    1,078,181,003.19
    三、本期增减变动金额(减少
    以“-”号填列)                 95,918,467.00     -95,918,467.00      17,716,267.11    119,849,293.91   -162,985.86   28,710,245.66       166,112,820.82
    (一)净利润                                                                            180,728,871.33                  2,484,264.34       183,213,135.67
    (二)其他综合收益
    上述(一)和(二)小计                                                                  180,728,871.33                  2,484,264.34       183,213,135.67
    (三)所有者投入和减少资本                                                                               -162,985.86   26,225,981.32        26,062,995.46
    1.所有者投入资本                                                                                                      26,225,981.32        26,225,981.32
    3.其他                                                                                                  -162,985.86                           -162,985.86
    (四)利润分配                                                         17,716,267.11    -60,879,577.42                                     -43,163,310.31
    1.提取盈余公积                                                        17,716,267.11    -17,716,267.11
    2.提取一般风险准备
    3.对所有者(或股东)的分配                                                             -43,163,310.31                                     -43,163,310.31
    (五)所有者权益内部结转         95,918,467.00     -95,918,467.00
    1.资本公积转增资本(或股本)    95,918,467.00     -95,918,467.00
    (六)专项储备
    (七)其他
    四、本期期末余额                415,646,691.00     238,318,072.13     100,134,392.44    455,654,287.57   -579,640.10   35,120,020.97    1,244,293,824.01
    法定代表人:肖 伟                                       主管会计工作负责人:陈友龙                                     会计机构负责人:焦晓杉
    第 17 页 共 20 页
    江苏康缘药业股份有限公司   (股票代码:600557)                                                                        2011 年半年度报告摘要
    母公司所有者权益变动表
    2011 年 1—6 月
    单位:元 币种:人民币
    本期金额
    项   目                        实收资本                       专项                      一般风
    资本公积                 盈余公积                 未分配利润       所有者权益合计
    (或股本)                       储备                      险准备
    一、上年年末余额                         415,646,691.00     238,318,072.13             98,327,231.88            448,900,700.64    1,201,192,695.65
    二、本年年初余额                         415,646,691.00     238,318,072.13             98,327,231.88            448,900,700.64    1,201,192,695.65
    三、本期增减变动金额(减少以“-”
    7,600,000.00     55,708,000.00                                       69,094,469.45      132,402,469.45
    号填列)
    (一)净利润                                                                                                     94,033,270.91       94,033,270.91
    (二)其他综合收益
    上述(一)和(二)小计                                                                                           94,033,270.91       94,033,270.91
    (三)所有者投入和减少资本                  7,600,000.00     55,708,000.00                                                           63,308,000.00
    1.所有者投入资本                           7,600,000.00     55,708,000.00                                                           63,308,000.00
    2.股份支付计入所有者权益的金额
    (四)利润分配                                                                                                  -24,938,801.46      -24,938,801.46
    1.提取盈余公积
    2.提取一般风险准备
    3.对所有者(或股东)的分配                                                                                     -24,938,801.46      -24,938,801.46
    (五)所有者权益内部结转
    (六)专项储备
    (七)其他
    四、本期期末余额                         423,246,691.00     294,026,072.13             98,327,231.88            517,995,170.09    1,333,595,165.10
    法定代表人:肖 伟                                          主管会计工作负责人:陈友龙                              会计机构负责人:焦晓杉
    第 18 页 共 20 页
    江苏康缘药业股份有限公司   (股票代码:600557)                                                                              2011 年半年度报告摘要
    上年同期金额
    项   目                    实收资本                        专项                        一般风
    资本公积                   盈余公积                  未分配利润        所有者权益合计
    (或股本)                      储备                        险准备
    一、上年年末余额                        319,728,224.00   334,236,539.13              80,610,964.77             332,617,606.95     1,067,193,334.85
    二、本年年初余额                        319,728,224.00   334,236,539.13              80,610,964.77             332,617,606.95     1,067,193,334.85
    三、本期增减变动金额(减少以“-”
    95,918,467.00   -95,918,467.00              17,716,267.11             116,283,093.69       133,999,360.80
    号填列)
    (一)净利润                                                                                                   177,162,671.11       177,162,671.11
    (二)其他综合收益
    上述(一)和(二)小计                                                                                         177,162,671.11       177,162,671.11
    (三)所有者投入和减少资本
    1.所有者投入资本
    2.股份支付计入所有者权益的金额
    (四)利润分配                                                                       17,716,267.11             -60,879,577.42       -43,163,310.31
    1.提取盈余公积                                                                      17,716,267.11             -17,716,267.11
    2.提取一般风险准备
    3.对所有者(或股东)的分配                                                                                    -43,163,310.31       -43,163,310.31
    (五)所有者权益内部结转                 95,918,467.00   -95,918,467.00
    1.资本公积转增资本(或股本)            95,918,467.00   -95,918,467.00
    (六)专项储备
    (七)其他
    四、本期期末余额                        415,646,691.00   238,318,072.13              98,327,231.88             448,900,700.64     1,201,192,695.65
    法定代表人:肖 伟                                        主管会计工作负责人:陈友龙                                   会计机构负责人:焦晓杉
    第 19 页 共 20 页
    江苏康缘药业股份有限公司   (股票代码:600557)       2011 年半年度报告摘要
    7.3 本报告期无会计政策、会计估计的变更。
    7.4 本报告期无前期会计差错更正。
    第 20 页 共 20 页